Compare SUPN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | WVE |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2012 | 2015 |
| Metric | SUPN | WVE |
|---|---|---|
| Price | $49.87 | $13.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $61.60 | $29.94 |
| AVG Volume (30 Days) | 632.9K | ★ 4.1M |
| Earning Date | 02-24-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $681,539,000.00 | $109,230,000.00 |
| Revenue This Year | $8.32 | N/A |
| Revenue Next Year | $23.64 | $16.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.54 | ★ 103.75 |
| 52 Week Low | $29.16 | $5.28 |
| 52 Week High | $57.65 | $21.73 |
| Indicator | SUPN | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 45.52 |
| Support Level | $49.41 | $13.72 |
| Resistance Level | $52.34 | $15.97 |
| Average True Range (ATR) | 1.62 | 1.34 |
| MACD | -0.21 | -0.50 |
| Stochastic Oscillator | 38.94 | 9.08 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.